trending Market Intelligence /marketintelligence/en/news-insights/trending/100_yadbmdsnx8-udqadya2 content esgSubNav
In This List

Adaptimmune raises $100M in offering of American depositary shares

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Adaptimmune raises $100M in offering of American depositary shares

Adaptimmune Therapeutics PLC sold 10 million American depositary shares at $10 apiece in a registered direct offering, raising net proceeds of about $100 million.

The U.K.-based biopharmaceutical company will use the proceeds to further develop its pipeline of specific peptide enhanced affinity receptor T-cell candidates through clinical trials.

Adaptimmune is currently developing its drug candidates MAGE-A4, MAGE-A10 and AFP to treat multiple solid tumor indications.

The company will also use a portion of the proceeds for other general corporate purposes.

Matrix Capital Management Co. LP, New Enterprise Associates 16 LP, New Enterprise Associates 14 LP and Syncona Portfolio Ltd. participated in the transaction.